½ÃÀ庸°í¼­
»óǰÄÚµå
1612617

¼¼°èÀÇ Ç÷¾×Çü ŸÀÌÇÎ ½ÃÀå : ±â¼ú, °Ë»ç À¯Çü, Á¦Ç° À¯Çü, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(2025-2030³â)

Blood Group Typing Market by Techniques (Assay-Based Techniques, Massively Parallel Sequencing, Microarray), Test Type (ABO Blood Tests, Antibody Screening, Antigen Typing), Product, End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 184 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Ç÷¾×Çü ŸÀÌÇÎ ½ÃÀåÀº 2023³â¿¡ 33¾ï 7,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 36¾ï 3,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 7.82%·Î ¼ºÀåÇϰí, 2030³â¿¡´Â 57¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Ç÷¾×Çü ŸÀÌÇÎÀº °³ÀÎÀÇ Ç÷¾×Çü°ú Rh ÀÎÀÚ¸¦ °áÁ¤ÇÏ´Â Áß¿äÇÑ Áø´Ü °úÁ¤À̸ç, ¾ÈÀüÇÑ ¼öÇ÷, Àå±â À̽Ä, Ãâ»ý Àü Äɾ ÇʼöÀûÀÔ´Ï´Ù. Áß¿äÇÏ°í »ý¸íÀ» À§ÇùÇÒ ¼ö ÀÖ´Â ¼º ¸é¿ª ¹ÝÀÀÀ» ¹æÁöÇϱâ À§ÇØ ÀûÇÕ¼ºÀ» º¸ÀåÇÕ´Ï´Ù. Ç÷¾×°Ë»ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ °ßÀÎÇÕ´Ï´Ù. ÀÚµ¿ ŸÀÌÇÎ ½Ã½ºÅÛ°ú µðÁöÅРŸÀÌÇÎ ½Ã½ºÅÛ°ú °°Àº »ó´çÇÑ ±â¼ú Áøº¸·Î ¼Óµµ¿Í Á¤È®¼ºÀÌ Çâ»óµÇ°í À̰ÍÀÌ Áß¿äÇÑ ÃËÁø¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. Àα¸ÀÇ °í·ÉÈ­¿Í ¼öÇ÷À» ÇÊ¿ä·ÎÇÏ´Â Áúº´ Áõ°¡µµ ½ÃÀå ¼ö¿ä¸¦ Áõ°¡ ½ÃÄ×½À´Ï´Ù. »ç¶÷µéÀÇ ÇÊ¿ä¿Í °°Àº ¹®Á¦¿¡ Á÷¸é ÇØ ÀÖ½À´Ï´Ù. ºñ¿ë È¿À²ÀûÀÌ°í »ç¿ëÇϱ⠽¬¿î ±â¼ú°ú °ß°íÇÑ ¿¬¼ö ÇÁ·Î±×·¥À» °³¹ßÇÔÀ¸·Î½á ÀÌ·¯ÇÑ Á¦¾à¿¡ ´ëóÇÏ´Â °ÍÀÌ Ãß°¡ ¼ºÀåÀ» °¡¼ÓÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á ¼Ö·ç¼Ç°ú °°Àº Çõ½ÅÀº À¯¸ÁÇÑ ¿¬±¸ ºÐ¾ß¸¦ ³ªÅ¸³À´Ï´Ù. À̸¦ À§ÇØ °Ç°­ °ü¸® Á¦°ø¾÷ü¿Í Çù·ÂÇÏ¸é ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·± Àå¾Ö¹°¿¡µµ ºÒ±¸Çϰí, ±â¼ú Çõ½Å°ú ÇコÄÉ¾î ¾×¼¼½ºÀÇ È®´ë°¡ ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 33¾ï 7,000¸¸ ´Þ·¯
ÃßÁ¤³â(2024) 36¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 57¾ï 2,000¸¸ ´Þ·¯
CAGR(%) 7.82%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â Ç÷¾×Çü ŸÀÌÇÎ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Ç÷¾×Çü ŸÀÌÇÎ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ȹµæÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡ ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¶Ç´Â ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ±³Åë»ç°í, ±ä±Þ»çÅÂ, ¿Ü»ó Áõ°¡
    • ¹ýÀÇÇп¡¼­ÀÇ Ç÷¾×Çü ŸÀÌÇΠä¿ë Áõ°¡
    • ¼öÇ÷¿¡ °üÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Àνİú ¼÷·ÃµÈ Àü¹®°¡ÀÇ ºÎÁ·
  • ½ÃÀå ±âȸ
    • Ç÷¾×Çü ŸÀÌÇÎ ½Ã½ºÅÛÀÇ Áøº¸¿Í °³¹ß
    • Ç÷¾×Çü ŸÀÌÇÎÀÇ ¿¬±¸ °³¹ß Ȱµ¿°ú Á¦Ç° Çõ½Å Áõ°¡
  • ½ÃÀåÀÇ °úÁ¦
    • º¯¼Ó±â¿Í °ü·ÃµÈ À§Çè

Porter's Five Force : Ç÷¾×Çü ŸÀÌÇÎ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Force ÇÁ·¹ÀÓ ¿öÅ©´Â Ç÷¾×Çü ŸÀÌÇÎ ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Force Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂûÀ» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Ç÷¾×Çü ŸÀÌÇÎ ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Ç÷¾×Çü ŸÀÌÇÎ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇϴµ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : Ç÷¾×Çü ŸÀÌÇÎ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

Ç÷¾×Çü ŸÀÌÇÎ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : Ç÷¾×Çü ŸÀÌÇÎ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Ç÷¾×Çü ŸÀÌÇÎ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : Ç÷¾×Çü ŸÀÌÇÎ ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

Ç÷¾×Çü ŸÀÌÇÎ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ´É·Â ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ±³Åë»ç°í, ±ä±Þ»çÅÂ, ¿Ü»ó Áõ°¡
      • ¹ýÀÇÇп¡ À־ÀÇ Ç÷¾×Çü ŸÀÌÇÎÀÇ Ã¤¿ë Áõ°¡
      • ¼öÇ÷¿¡ °üÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØ
    • ¾ïÁ¦¿äÀÎ
      • Àνİú ¼÷·ÃµÈ Àü¹®°¡ÀÇ ºÎÁ·
    • ±âȸ
      • Ç÷¾×Çü ŸÀÌÇÎ ½Ã½ºÅÛÀÇ Áøº¸¿Í ¹ßÀü
      • Ç÷¾×Çü ŸÀÌÇο¡ À־ÀÇ ¿¬±¸°³¹ß Ȱµ¿°ú Á¦Ç° Çõ½ÅÀÇ °­È­
    • °úÁ¦
      • Àü¿°º´¿¡ µû¸¥ À§Çè
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • ±â¼ú: ºÐ¼® ±â¹Ý ¹× ´ë±Ô¸ð º´·Ä ½ÃÄö½Ì ±â¼ú äÅà Áõ°¡
    • °Ë»çÀÇ À¯Çü: Ç׿øÀ» °ËÃâÇϱâ À§ÇÑ ABO Ç÷¾× °Ë»ç¿Í Àΰ£ ¹éÇ÷±¸ Ç׿ø ŸÀÌÇÎ °Ë»çÀÇ ±Þ¼ÓÇÑ ÃâÇö
    • Á¦Ç°: Ç÷¾×Çü ŸÀÌÇÎ ¼­ºñ½º¿¡¼­ ¼Ò¸ðǰ ¹× ±â±¸ÀÇ Áß¿äÇÑ »ç¿ë
    • ÃÖÁ¾ »ç¿ëÀÚ : ÀÓ»ó ½ÇÇè½Ç ¹× º´¿ø¿¡¼­ Ç÷¾×Çü ŸÀÌÇÎ ¼­ºñ½ºÀÇ »õ·Î¿î ÀÌ¿ë
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå Ç÷¾×Çü ŸÀÌÇÎ ½ÃÀå : ±â¼úº°

  • ºÐ¼® ±â¹Ý ±â¼ú
  • Ãʺ´·Ä ½ÃÄö½Ì
  • ¸¶ÀÌÅ©·Î¾î·¹ÀÌ

Á¦7Àå Ç÷¾×Çü ŸÀÌÇÎ ½ÃÀå : °Ë»ç À¯Çüº°

  • ABO Ç÷¾× °Ë»ç
  • Ç×ü ½ºÅ©¸®´×
  • Ç׿øÇü ÆÇÁ¤
  • Å©·Î½º ¸ÅĪ °Ë»ç
  • Àΰ£ ¹éÇ÷±¸ Ç׿ø ŸÀÌÇÎ

Á¦8Àå Ç÷¾×Çü ŸÀÌÇÎ ½ÃÀå : Á¦Ç°º°

  • ¼Ò¸ðǰ
  • ±â±â
  • ¼­ºñ½º

Á¦9Àå Ç÷¾×Çü ŸÀÌÇÎ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • Ç÷¾×ÀºÇà
  • ÀÓ»ó ½ÇÇè½Ç
  • º´¿ø

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ Ç÷¾×Çü ŸÀÌÇÎ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Ç÷¾×Çü ŸÀÌÇÎ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ç÷¾×Çü ŸÀÌÇÎ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • My Personal Health Bank°¡ Eldon Biologicals A/S¿Í Á¦ÈÞÇØ, POC Ç÷¾×Çü °Ë»ç¸¦ Â¥³ÖÀº Çõ½ÅÀûÀÎ ÇコÄÉ¾î ¼Ö·ç¼ÇÀ» Á¦°ø
    • Metropolis Healthcare°¡ HSCT¿Í °íÇü Àå±â À̽ÄÀÇ °Ë»ç¸¦ °³½Ã
    • NHSBTÀÇ ¿¬±¸ÀÚ°¡ »õ·Î¿î Ç÷¾×Çü ½Ã½ºÅÛÀ» ¹ß°ß
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Agena Bioscience, Inc.
  • Atlas Medical GmbH
  • AXO Science SAS
  • BAG Health Care GmbH
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc
  • Biorex Diagnostics
  • Cardinal Health
  • Genome Diagnostics BV
  • Grifols, SA
  • Hemo bioscience, Inc.
  • Lorne Laboratories Limited
  • Merck KGaA
  • Quotient Suisse SA
  • Rapid Labs Ltd
  • Thermo Fisher Scientific, Inc.
JHS 24.12.24

The Blood Group Typing Market was valued at USD 3.37 billion in 2023, expected to reach USD 3.63 billion in 2024, and is projected to grow at a CAGR of 7.82%, to USD 5.72 billion by 2030.

Blood group typing is a critical diagnostic process that determines an individual's blood type and Rh factor, essential for safe blood transfusions, organ transplants, and prenatal care. This procedure is crucial in medical emergencies, routine healthcare, and research, ensuring compatibility to prevent potentially life-threatening immune responses. The market for blood group typing is expanding due to rising awareness about blood safety, increased surgical procedures, and chronic disease prevalence, which drive the demand for reliable blood testing. Significant technological advancements, such as automated and digital typing systems, enhance speed and accuracy, which are critical growth drivers. Moreover, growing investments in healthcare infrastructure in emerging economies present opportunities for market expansion. The aging population, coupled with increasing cases of disorders requiring blood transfusions, also augments market demand. However, the market faces challenges like high costs of advanced typing systems, regulatory hurdles, and the need for skilled technicians. Addressing these constraints by developing cost-effective, user-friendly technologies and robust training programs could foster further growth. Innovations such as point-of-care testing devices, integration with AI for predictive analytics, and personalized medical solutions represent promising research areas. Additionally, increased R&D efforts towards creating universal blood alternatives could revolutionize the field. Collaborating with healthcare providers to enhance awareness through education campaigns may also promote market growth. Conversely, limited awareness in low-income regions, potential for false negatives, and technical complexities pose challenges. Despite these hurdles, the market is poised for growth, driven by technological innovations and expanding healthcare access. Strategic investments in R&D, partnerships focusing on technological integration, and harnessing emerging market potentials will be key to capitalizing on the opportunities in blood group typing.

KEY MARKET STATISTICS
Base Year [2023] USD 3.37 billion
Estimated Year [2024] USD 3.63 billion
Forecast Year [2030] USD 5.72 billion
CAGR (%) 7.82%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Blood Group Typing Market

The Blood Group Typing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing cases of road accidents, emergencies, and trauma
    • Rising adoption of blood group typing in forensic sciences
    • Strict regulatory standards regarding blood transfusion
  • Market Restraints
    • Lack of awareness and skilled professional
  • Market Opportunities
    • Advancements and developments in the blood group typing systems
    • Increasing R&D activities and product innovations in blood group typing
  • Market Challenges
    • Risk associated with transmissible diseases

Porter's Five Forces: A Strategic Tool for Navigating the Blood Group Typing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Blood Group Typing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Blood Group Typing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Blood Group Typing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Blood Group Typing Market

A detailed market share analysis in the Blood Group Typing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Blood Group Typing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Blood Group Typing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Blood Group Typing Market

A strategic analysis of the Blood Group Typing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Blood Group Typing Market, highlighting leading vendors and their innovative profiles. These include Agena Bioscience, Inc., Atlas Medical GmbH, AXO Science SAS, BAG Health Care GmbH, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc, Biorex Diagnostics, Cardinal Health, Genome Diagnostics B.V., Grifols, S.A., Hemo bioscience, Inc., Lorne Laboratories Limited, Merck KGaA, Quotient Suisse SA, Rapid Labs Ltd, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Blood Group Typing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Techniques, market is studied across Assay-Based Techniques, Massively Parallel Sequencing, and Microarray.
  • Based on Test Type, market is studied across ABO Blood Tests, Antibody Screening, Antigen Typing, Cross-Matching Series, and Human Leukocyte Antigen Typing.
  • Based on Product, market is studied across Consumables, Instruments, and Services.
  • Based on End-User, market is studied across Blood Banks, Clinical Laboratories, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing cases of road accidents, emergencies, and trauma
      • 5.1.1.2. Rising adoption of blood group typing in forensic sciences
      • 5.1.1.3. Strict regulatory standards regarding blood transfusion
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of awareness and skilled professional
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements and developments in the blood group typing systems
      • 5.1.3.2. Increasing R&D activities and product innovations in blood group typing
    • 5.1.4. Challenges
      • 5.1.4.1. Risk associated with transmissible diseases
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Techniques: Increasing adoption of assay-based and massively Parallel Sequencing techniques
    • 5.2.2. Test Type: Rapid emergence of ABO blood tests and human leukocyte antigen typing tests to detect the antigens
    • 5.2.3. Product: Significant use of consumables and instruments in blood group typing services
    • 5.2.4. End-User: Emerging use of blood group typing services in clinical laboratories and hospitals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Blood Group Typing Market, by Techniques

  • 6.1. Introduction
  • 6.2. Assay-Based Techniques
  • 6.3. Massively Parallel Sequencing
  • 6.4. Microarray

7. Blood Group Typing Market, by Test Type

  • 7.1. Introduction
  • 7.2. ABO Blood Tests
  • 7.3. Antibody Screening
  • 7.4. Antigen Typing
  • 7.5. Cross-Matching Series
  • 7.6. Human Leukocyte Antigen Typing

8. Blood Group Typing Market, by Product

  • 8.1. Introduction
  • 8.2. Consumables
  • 8.3. Instruments
  • 8.4. Services

9. Blood Group Typing Market, by End-User

  • 9.1. Introduction
  • 9.2. Blood Banks
  • 9.3. Clinical Laboratories
  • 9.4. Hospitals

10. Americas Blood Group Typing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Blood Group Typing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Blood Group Typing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. My Personal Health Bank Joins Forces with Eldon Biologicals A/S for Innovative Healthcare Solutions incorporating POC Blood Typing
    • 13.3.2. Metropolis Healthcare launches test for HSCT & solid organ transplantation
    • 13.3.3. NHSBT Researchers Discover New Blood Group System
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Agena Bioscience, Inc.
  • 2. Atlas Medical GmbH
  • 3. AXO Science SAS
  • 4. BAG Health Care GmbH
  • 5. Beckman Coulter, Inc.
  • 6. Bio-Rad Laboratories, Inc
  • 7. Biorex Diagnostics
  • 8. Cardinal Health
  • 9. Genome Diagnostics B.V.
  • 10. Grifols, S.A.
  • 11. Hemo bioscience, Inc.
  • 12. Lorne Laboratories Limited
  • 13. Merck KGaA
  • 14. Quotient Suisse SA
  • 15. Rapid Labs Ltd
  • 16. Thermo Fisher Scientific, Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦